ArticleThe mental health clinician2018
Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis.
Article in The mental health clinician, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.PloS one · 2022Pooled it
- Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system.BMJ open · 2023Trial
- The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia.CNS drugs · 2026Review
- What is Minimally Adequate Treatment of Psychosis and Should Duration of Inadequate Treatment be a Clinical and Research Target? A Perspective and State-of-the-Art Review.Schizophrenia bulletin · 2026Review
- Treatment outcomes of an integrated treatment model for patients with co-occurring opioid use and schizophrenia spectrum disorders.Frontiers in psychiatry · 2026Article
- Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study.Therapeutic advances in psychopharmacology · 2026Article
- Characteristics and Utilization Patterns of Medicare Beneficiaries Initiating Long-Acting Injectable Antipsychotic Medications.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Medication utilization patterns among patients with rheumatoid arthritis and coexisting autoimmune conditions.Journal of managed care & specialty pharmacy · 2025Article
- Drug Utilization and Medication Adherence: A Data-Driven Analysis of Drugs with Different Routes of Administration Applied in Atopic Dermatitis.Pharmaceutics · 2025Article
- Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study.Healthcare (Basel, Switzerland) · 2025Article
- Appropriate use of single-dose injectable aripiprazole lauroxil in the treatment of schizophrenia.The mental health clinician · 2024Article
- Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients.International journal of circumpolar health · 2023Article
- Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives.Implementation science communications · 2023Article
- Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.Pharmaceutics · 2023Article
- Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer.The Journal of urology · 2023Review
- Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study.Frontiers in psychiatry · 2023Article
- Article
- Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.Nature communications · 2022Article
- Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners.The mental health clinician · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite the theory that long-acting injectable (LAI) antipsychotics should be more likely to improve adherence, reduce gaps in therapy, and prevent relapse compared with oral antipsychotics, there is little published evidence on this issue, specifically in patients with early psychosis.
methodsPatients with a new diagnosis for a psychotic disorder between July 1, 2013, and August 31, 2014, were retrospectively evaluated during a 12-month duration. The primary outcomes were adherence and persistence. Adherence was determined by proportion of days with medication, and persistence was defined as zero gaps in medication therapy. The secondary outcome was the number of times a psychiatric acute care service was used. Patients were divided into 3 groups based on their antipsychotic prescription history: oral only, LAI only, or both formulations at separate times throughout the study period.
resultsForty-seven patients met inclusion criteria. The average proportions of days with medication were 32%, 76%, and 75% for the oral, LAI, and both formulations groups, respectively ( DISCUSSION: Long-acting injectable antipsychotics were associated with better adherence compared with oral antipsychotics in patients with early psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.